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Context: Inactivating mutations in the enzyme hexose-6-phosphate dehydrogenase (H6PDH, encoded
by H6PD) cause apparent cortisone reductase deficiency (ACRD). H6PDH generates cofactor NADPH
for 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1, encoded by HSD11B1) oxo-reductase
activity, converting cortisone to cortisol. Inactivating mutations in HSD11B1 cause true cortisone
reductase deficiency (CRD). Both ACRD and CRD present with hypothalamic-pituitary-adrenal (HPA)
axis activation and adrenal hyperandrogenism.
Objective: To describe the clinical, biochemical and molecular characteristics of two additional female
children with ACRD and to illustrate the diagnostic value of urinary steroid profiling in identifying
and differentiating a total of six ACRD and four CRD cases.
Design: Clinical, biochemical and genetic assessment of two female patients presenting during
childhood. In addition, results of urinary steroid profiling in a total of ten ACRD/CRD patients were
compared to identify distinguishing characteristics.
Results: Case 1 was compound heterozygous for R109AfsX3 and a novel P146L missense mutation in
H6PD. Case 2 was compound heterozygous for novel nonsense mutations Q325X and Y446X in H6PD.
Mutant expression studies confirmed loss of H6PDH activity in both cases. Urinary steroid metabolite
profiling by gas chromatography/mass spectrometry suggested ACRD in both cases. In addition, we
were able to establish a steroid metabolite signature differentiating ACRD and CRD, providing a basis
for genetic diagnosis and future individualised management.
Conclusions: Steroid profile analysis of a 24-h urine collection provides a diagnostic method for
discriminating between ACRD and CRD. This will provide a useful tool in stratifying unresolved
adrenal hyperandrogenism in children with premature adrenarche and adult females with polycystic
ovary syndrome (PCOS).
European Journal of Endocrinology 168 K19–K26Introduction
Cortisone reductase deficiency (CRD) and apparent CRD
(ACRD) are characterised by the failure to generate
cortisol from inactive cortisone resulting in HPA axis
activation and excessive ACTH-mediated adrenal andro-
gen secretion, with w14 cases described clinically and
biochemically in the literature (1, 2, 3, 4, 5, 6, 7, 8, 9).
Affected patients may present with premature adrenarche
in childhood including pubarche, or as adolescents and
adults with androgen excess and a PCOS-like phenotype in
females (4, 5, 10). A 24-h urine collection subjected to
urinary steroid analysis by gas chromatography/mass
spectrometry (GC/MS) shows characteristic elevations
of cortisone metabolites (tetrahydrocortisone (THE))ndocrinology
e distributed under the terms of the European J
nd reproduction in any medium, provided the orirelative to cortisol metabolites (tetrahydrocortisol
(THFC5a-THF)) together with a decrease in 5a/5b
tetrahydrocortisol. Additionally, metabolites of the andro-
genic precursors androsterone (An), etiocholanolone (Et)
and DHEA/S are pathologically elevated.
The HSD11B1 gene encodes the enzyme
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1)
that functions as an NADPH-dependent oxo-reductase
within the lumen of the endoplasmic reticulum (ER)
converting inactive cortisone to active cortisol.
Mutations in HSD11B1 explain CRD that leads to loss
of cortisol regeneration and increased cortisol clearance
with secondary activation of the HPA axis (5, 11). By
contrast, ACRD is caused by mutations in the H6PD
gene, which encodes the enzyme hexose-6-phosphateDOI: 10.1530/EJE-12-0628
Online version via www.eje-online.org
ournal of Endocrinology’s Re-use Licence which permits unrestricted non-
ginal work is properly cited.
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generates cofactor NADPH that is utilised by 11b-HSD1
for the conversion of cortisone to cortisol (4). Inacti-
vation of H6PDH in mice and humans leads not only
to the loss of 11b-HSD1 oxo-reductase activity but
also to a gain of 11b-HSD1 dehydrogenase activity, with
a profound switch to cortisol inactivation (4, 12). In
recombinant mice lacking H6PDH and 11b-HSD1, the
urinary steroid profile abnormality is more marked in
H6PDKO mice compared with 11b-HSD1KO mice (13).
To date, we have identified two patients with CRD
(boys aged 8 and 11 years) with significantly reduced
THFC5a-THF/THE ratios of 0.16 and 0.22 (reference
range 0.7–1.3). As for ACRD, we have identified four
cases (one boy aged 6 years and three adult females) with
an even more extreme biochemical phenotype typified
by very low THFC5a-THF/THE ratios!0.05 (4, 5).
Here, we describe two new female cases aged 4 and
7 years presenting with premature adrenarche. Employ-
ing our GC/MS-derived biomarker panel and molecular
genetic analysis, we establish a diagnosis of ACRD with
novel mutations in H6PD in both patients, highlighting
the first presentation of ACRD in female children.
Furthermore, we define the diagnostic urinary steroid
metabolite profiles differentiating CRD/ACRD and
propose a diagnostic and therapeutic strategy for the
clinical management of affected individuals to pre-
vent potential long-term health problems including
hyperandrogenism.Materials and methods
Patients
Approval for all studies was obtained after seeking
consent according to Local Institutional Review Board
criteria. Both cases were minors and parental consent
was obtained.
Case 1 was a 7-year-old girl of non-consanguineous
Caucasian parents who presented with an 8-month
history of premature pubarche with onset of pubic and
axillary hair (Tanner P2, A2, B1), as well as increased
height velocity. On examination, she was 24.9 kg (0.21
SDS) and 129.5 cm (0.95 SDS) in height. Her bone age
was accelerated at 8.8 years. Central precocious
puberty was excluded by a pre-pubertal response to
a LHRH stimulation test (LH baseline: 0.2 mU/ml,
30 min 1.5 mU/ml; FSH baseline: 3.2 mU/ml, 30 min
8.5 mU/ml) and infantile appearance and volume
(1.5 ml) of the uterus on ultrasound. However, adrenal
androgens were elevated with a DHEA of 21.1 nmol/l
(normal range (NR), 3.5–10.4 nmol/l) and androstene-
dione of 2.2 nmol/l (NR, 0.2–1.2 nmol/l).
Case 2 was a 4-year-old girl, the first child of
non-consanguineous Caucasian parents, referred for
investigation of premature pubarche. From the age of 3.5
years, she developed hair around the labia majora andwww.eje-online.orga distinct change in body odour, with no acne or growth
acceleration. On examination, she was 19.8 kg (1.2 SDS)
and 108.5 cm in height (1.01 SDS), with Tanner stage
2 pubic hair, no breast development, no clitoromegaly
and normal blood pressure. She had an accelerated bone
age of 5 years. Her LH (!0.1 IU/l; NR, 0.1–0.4 IU/l) and
FSH (1.3 IU/l; NR, 0.23–11.1 IU/l) were appropriate for
age and not suggestive of central precocious puberty.
Morning DHEAS (4.05 mmol/l; NR, 0.05–0.85 mmol/l)
and androstenedione (1.9 nmol/l; NR, 0.2–1.2 nmol/l)
were elevated but 17-OH-progesterone and ACTH were
normal. Testosterone was undetectable and SHBG was
decreased; 0900 h baseline cortisol was 90.2 nmol/l
with an exaggerated response 60 min after cosyntropin
stimulation (1.336 nmol/l; NRO550 nmol/l). At age
7 years, she had a slightly increased linear growth
rate and advanced bone age of 9 years. DHEAS had
increased to 9.72 mmol/l and androstenedione to
4.8 nmol/l. Adrenal ultrasound was normal.Urinary steroid metabolite analysis
The two novel ACRD cases were assessed by urinary
steroid profile analysis employing GC/MS of 24-h urine
collections. They were then compared with the steroid
profiles of the four previously described cases of ACRD
and two cases of CRD (4, 5). Urinary steroid metabolite
excretion was analysed employing a previously
described GC/MS selected-ion-monitoring method
(GC/MS-SIM) (4, 5, 9). In brief, steroids were
enzymatically released from conjugation and, after
extraction, chemically derivatised before GC/MS-SIM.
Metabolites of the glucocorticoid series were THF,
5a-THF, a-cortol, a-cortolone, b-cortol, b-cortolone,
THE and urinary cortisol and cortisone. Androgen
metabolites were An, Et and DHEA. After quantification
of steroid metabolites by GC/MS, we also calculated
substrate/product metabolite ratios and ratios of cortisol
or cortisone metabolites as an index of the in vivo
activity of 11b-HSD1 (THFC5a-THF/THE and cortols/
cortolones) and the 5a/5b-reductases (THF/5a-THF).
As a measure of HPA axis activity, the sum of the
glucocorticoid series was defined as total cortisol
metabolite excretion (THFsCTHECcortolsCcortolo-
nesCurinary cortisolCurinary cortisone) and total
androgen excretion as the sum of androgen metabolites
(AnCEtCDHEA). Diagnostic ratios and the overall
secretion patterns were compared with urinary steroid
profiles obtained from a normal reference cohort of
healthy children of different age groups (group 1: age
1–7 years, nZ22, 12 boys and 10 girls; group 2: age
8–14 years, nZ31, 13 boys and 18 girls) and adult
females (age 18–63 years; nZ82).Molecular analysis of HSD11B1 and H6PD
PCR amplification of the coding region of both genes
including exon/intron boundaries was performed using
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(4, 5). We compared HSD11B1 sequences with
GenBank entries for two overlapping clones covering
chromosome 1q32.2–41, PAC 28010, PAC 43014 and
H6PD sequences to clone RP3-510D11 on chromosome
1p36.2–36.3.Mutagenesis and stable cell line generation
The QuikChange Site-Directed Mutagenesis Kit (Strata-
gene, Cambridge, UK) was used to mutate WT H6PD
cDNA, contained in pcDNA3.1D/V5-His-TOPO (Invi-
trogen), to the respective alternative mutant sequences,
with subsequent confirmation of the introduced
mutations by direct sequencing. HEK293 cells were
transfected with WT and mutant H6PD using a 293
cell-specific transfection reagent (Mirus, Birmingham,
UK). Stably transfected cells were selected using G418
(Sigma) and, in each case, four clones from single-cell
colonies were derived for WT and mutant enzyme
studies.RNA extraction RT-PCR
As described previously (4), total RNA was extracted
from transfected cell lines using a single-step extraction
method (Tri-reagent, Sigma) and 1 mg total RNA reverse
transcribed to cDNA (Applied Biosystems). Gene
expression was assessed using pre-validated specific
TaqMan gene expression assays and Universal PCR
Master Mix (Applied Biosystems). Expression levels were
normalised to the housekeeping gene 18S in all.Table 1 Urine steroid metabolome of two novel ACRD cases.H6PDH assay
H6PDH assays were performed on WT and mutant
microsomes prepared from HEK293 cells by spectro-
fluorometric detection of NADPH generation as
described previously (nZ4 stable cell lines analysed in
triplicate) (4).Case 1 Case 2 Reference range
Glucocorticoid metabolites (mg/24 h)
THF 329 280 94–720
5a-THF 49 290 152–820
a-Cortol 14 22 11–87
b-Cortol 49 44 40–302
THE 6663 5382 235–1781
a-Cortolone 738 640 61–530
b-Cortolone 1317 664 64–475
Sum of glucocorticoid
metabolites
9159 7322 832–4312
Diagnostic ratios
5a-THFCTHF/THE 0.06 0.1 0.7–1.3
Cortols/cortolones 0.03 0.03 0.26–0.50
Androgen metabolites (mg/24 h)
An 268 919 2–254
Et 180 276 1–184
DHEA 72 26 0.5–31
Sum of androgen
metabolites
520 1221 5–455Western blot analysis
Western blots were prepared by electroblotting 11%
SDS–polyacrylamide gels onto Immobilon PVDF mem-
branes (Millipore, Billerica, MA, USA) at 100 V for 1 h
in a buffer containing 25 mM Tris, 200 mM glycine
and 20% (v/v) methanol. Membrane was blocked in
PBS containing 0.1% (v/v) Tween 20 and 20% (w/v)
skimmed milk powder, washed and then incubated with
anti-H6PDH polyclonal antibody in PBS containing
0.05% (v/v) Tween 20. Membrane was then washed
and incubated with secondary antibody diluted
1/25 000 in PBS containing 0.05% (v/v) Tween 20.
Detection was by enhanced chemiluminescence
(Amersham Biosciences). Anti-calreticulin antibody
was used as a loading control.Results
Urinary steroid metabolite analysis of novel
ACRD cases
Table 1 summarises the urinary steroid metabolite
profiling of cases 1 and 2 and highlights the
diagnostically important findings. In both cases, the
metabolites of cortisol (THF, 5a-THF and the cortols)
were below or at the lower end of normal, whereas the
metabolites of cortisone (THE and the cortolones) were
elevated above the normal reference range in all cases.
To enhance interpretation of these individual meta-
bolites, we calculated THFC5a-THF/THE and cortols/
cortolones ratios and showed them to be grossly
abnormal in both cases, falling to near zero and well
below the normal reference range (Table 1). These data
strongly indicate a defect in the conversion of cortisone
to cortisol. As a consequence of the increased cortisol
clearance, total glucocorticoid output is elevated in both
cases above the normal reference range (Table 1). This
also results in increased ACTH-mediated adrenal
androgen output reflected in elevated levels of the
androgen metabolites (An, Et and DHEA) in both cases
(Table 1). From these urinary steroid profile data, it was
concluded that the clinical and biochemical evidence
were strongly suggestive of ACRD and warranted
genetic examination.H6PD genetic analysis
Case 1 was compound heterozygous for a previously
identified, paternally inherited c.325delC mutation
resulting in a frameshift with the generation of an
in-frame stop codon (p.R109AfsX3) severely truncating
the H6PDH protein. We also identified a novel
maternally inherited c.437COT mutation, generatingwww.eje-online.org
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conserved region of the H6PDH protein.
Case 2 was compound heterozygous for a c.973COT
nonsense mutation (p.Q325X) and a c.1338COG
nonsense mutation (p.Y446X) both of which generate
premature stop codons that severely truncate the
H6PDH protein (no parental DNA was available for
typing).H6PDH enzyme activity assays and protein
modelling
To examine the functional effects of the three novel
mutations on H6PDH enzyme activity, both mutant andWT
A
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www.eje-online.orgWT H6PDH sequences were used to transfect the
HEK293 mammalian cell line. Cells over-expressing
WT H6PDH had robust activity (Fig. 1A), whereas
mock-transfected cells had low H6PDH activity due to
endogenous levels of the enzyme. Activity in cells
transfected to similar levels (as evidenced by similar
mRNA expression) with the three mutant constructs
was indistinguishable from mock-transfected controls
(Fig. 1A), highlighting that these mutations were
indeed inactivating. Western blot analyses of total
microsomal proteins indicated that compared with
WT, p.P146L was produced at a similar level
(Fig. 1A). No H6PDH protein was detected from
p.Y446X or p.Q325X as the peptide sequence used to
raise the H6PDH antibody would be missing in these
truncated proteins (Fig. 1A). The region containing
p.P146 is not only conserved within H6PDH from a
variety of species but also present in the highly related
cytosolic protein, glucose-6-phosphate dehydrogenase
(G6PDH; Fig. 1B). In crystal structures of G6PDH, the
equivalent proline residue (Pro144), together with
the adjacent proline (Pro143), forms a turn close to
the coenzyme NADPC (Fig. 1B). Hydrogen bonding
between Pro143 and NADPC is known to contribute to
cofactor binding (14).Urinary steroid metabolome analysis and the
diagnostic spectrum of ACRD/CRD
To evaluate these newly defined ACRD cases in a
broader context, they were compared with the pre-
viously established ACRD and CRD cases we have
investigated (4, 5) using GC/MS analysis. As our
previously described CRD cases had a dominantFigure 1 Molecular analysis of novel H6PD mutations. (A) H6PDH
enzyme activity assays in HEK293 cells mock transfected or stably
transfected with the WT and mutant cDNA constructs expressed as
nmol NADPH/min per mg microsomal protein (meanGS.E.M.; nZ3).
Western blot analysis of microsomal proteins from HEK293-
transfected cells. H6PDH protein is clearly visible in cells
expressing both WT and P146L. No signal is visible for p.Y446X or
p.Q325X as the peptide sequence used to raise the H6PDH
antibody would be missing in these truncated proteins. Anti-
calreticulin antibody was used as a loading control. (B) Protein
alignments across species of both H6PDH and the related enzyme,
glucose-6-phosphate dehydrogenase (G6PDH), indicating signi-
ficant sequence conservation of the proline (P146L) residue
(marked with *). Ribbon representation of the crystal structure of
G6PDH (composite of two structures; PDB codes: 2BH9,
2BHL – chain A only). The glucose-6-phosphate substrate (G6P,
red) and coenzyme NADP (orange) bind at adjacent sites. Another
‘structural’ NADP (pink) binds some distance away. Right-hand
panel is a close-up of the coenzyme NADPC binding region
showing the proximity of the key proline residues (highlighted in
green) to the bound coenzyme. Structural images produced using
UCSF Chimera from the Resource for Biocomputing, Visualization,
and Informatics at the University of California, San Francisco (http://
www.cgl.ucsf.edu/chimera, supported by NIH P41 RR-01081) (19).
Full colour version of this figure available via http://dx.doi.org/10.
1530/EJE-12-0628.
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Figure 2 Urinary glucocorticoid metabolites
defining ACRD/CRD. (A) Children. All
diagnosed CRD/ACRD children (nZ5;
ACRD: closed circle, 6 years; closed
triangle, 7 years; closed square, 4 years;
CRD: open circle, 8 years; open triangle,
13 years) plotted on a log scale for a range
of glucocorticoid metabolites found in urine,
plotted against an age-matched reference
cohort (grey box plots: age 1–7 years,
nZ22, 12 boys and ten girls; white box
blots: age 8–14 years, nZ31, 13 boys and
18 girls). (B) Adult females. All diagnosed
CRD/ACRD adult females (nZ5; closed
symbols represent ACRD and white circles
represent CRD cases) plotted on a log
scale for a range of glucocorticoid meta-
bolites found in urine, plotted against an
age-matched reference cohort (age 18–63
years; nZ89). Box plots represent the
interquartile ranges (25th–75th percen-
tiles), and whiskers represent the 5th and
95th percentiles. For steroid abbreviation,
please refer to Patients and methods
section.
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affected parent (in both cases the mothers) should be
included in the analysis of their urine steroid metabo-
lome; hence, we present four urine profiles consistent
with CRD. To do this, we have generated a comparative
output with ACRD and CRD cases plotted against
normal age-matched reference ranges with box plots
representing the interquartile ranges (25th–75th
percentiles) and whiskers represent the 5th and 95th
percentiles respectively. Of the reference cohorts used,
we plotted on a log scale diagnostic ratios, glucocorti-
coid and adrenal androgen metabolite concentrations
and total cortisol and androgen metabolites to estimate
HPA activity and adrenal output as a further means
to diagnose and differentiate future cases of ACRD
and CRD.
In children, there is a propensity for lower cortisol
metabolite concentrations (THF, 5a-THF and cortols)
and a greater deviation from the age-related normal
range in cortisone metabolite concentrations (THE and
the cortolones) in ACRD compared with CRD cases,
with the data highlighting the need to compare these
values to specific age-related reference ranges (Fig. 2A).
Urinary cortisol and total cortisol metabolite values
were elevated above the normal age-related referencerange in ACRD cases and towards the top of the normal
range in CRD cases (Fig. 2A), possibly indicating a
greater degree of HPA axis activation in ACRD cases. As
for adult females, there is more clear demarcation
between CRD and ACRD, possibly as a result of
differential lifelong enhanced HPA activity. Again,
cortisol metabolites tend to be lower in ACRD cases,
but ACRD cases also have clear demarcation from CRD
cases in the elevated levels of cortisone metabolites.
ACRD cases also have higher urinary free cortisol and a
clear elevation of total cortisol metabolites compared
with CRD cases, with both being elevated above normal
output (Fig. 2B).
To enhance interpretation, we used diagnostic
substrate to product metabolite ratios: the well-
established THFC5a-THF/THE ratio and the cortol/
cortolone ratio as a further confirmatory ratio. The
normal range for these ratios does not differ signi-
ficantly between the age-related reference range cohorts
for all cases we have combined the data. For the THF
C5a-THF/THE ratio, this value is invariably %0.1 in
ACRD and for CRD R0.1 but %0.5, with the highest
CRD ratio recorded still below the normal range (Fig. 3).
This is in agreement within the cortol/cortolone ratio
with a similar pattern being observed (Fig. 3). Together,www.eje-online.org
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Figure 3 Urinary glucocorticoid metabolite ratios defining
ACRD/CRD. All previously diagnosed CRD/ACRD patients (nZ5
children, five adults where available) were plotted on a log scale for
their THFC5a-THF/THE, cortols/cortolones and 5a-THF/THF
ratios compared with a normal range of combined adults and
children, as there is no difference in these ratios between age
groups in their independent normal ranges. For all three ratios,
there is a similar demarcation between ACRD (closed shapes) and
CRD (open shapes) in most instances, with ACRD ratios being most
divergent from the normal range. Box plots represent the
interquartile ranges (25th–75th percentiles), and whiskers rep-
resent the 5th and 95th percentiles. Each symbol represents an
individual case-specific measurement, closed symbols for ACRD
cases and open symbols for CRD cases. For steroid abbreviation,
please refer to Patients and methods section.
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Figure 4 Urinary androgen metabolites defining ACRD/CRD. (A)
Children. All diagnosed CRD/ACRD children (nZ5; ACRD: closed
circle, 6 years; closed triangle, 7 years; closed square, 4 years;
CRD: open circle, 8 years; open triangle, 13 years) plotted on a log
scale for a range of androgen metabolites found in urine, plotted
against an age-matched reference cohort (grey box plots: age 1–7
years, nZ22, 12 boys and ten girls; white box blots: age 8–14 years,
nZ31, 13 boys and 18 girls). (B) Adult females. All diagnosed
CRD/ACRD adult females (nZ5; closed symbols represent ACRD
and open symbols represent CRD cases) plotted on a log scale for a
range of androgen metabolites found in urine, plotted against an
age-matched reference cohort (age 18–63 years; nZ89). Box plots
represent the interquartile ranges (25th–75th percentiles), and
whiskers represent the 5th and 95th percentiles. For steroid
abbreviation, please refer to Patients and methods section.
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and discriminating between CRD and ACRD. The
5a-THF/THF ratio is a marker of 5a/5b-reductase
activity and demonstrates that there is a preferential
5b-metabolism route in some but not all ACRD cases,
but the basis for this differential activity is unknown.
Finally, the functional consequence of reduced or
abolished 11b-HSD1 activity is HPA activation as
demonstrated by elevated total glucocorticoid output;
therefore, the same might be anticipated for adrenal
androgen output. Circulating serum androgens are
elevated in all cases, so we examined the urine androgen
metabolite profile also. In the urine of CRD and ACRD
children, there are elevations in adrenal-derived
androgens (An, Et and DHEA) above the normal range
and as a result increased total androgen output,
corroborating the increased total cortisol metabolite
output (Fig. 4A). It does not appear that CRD and ACRD
can be distinguished when compared with the degree ofwww.eje-online.orgdifference to their age-matched normal ranges, unlike
the total glucocorticoid metabolites that show a greater
degree of elevation above the age-matched normal
range in ACRDs. No significant differences were
observed between adult female cases, though there is
a tendency towards the CRD cases having more
pronounced androgen output with values towards the
top of the normal range (Fig. 4B).
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Here, we provide the biochemical and genetic basis
for two novel cases of ACRD due to H6PDH deficiency
in girls presenting with premature adrenarche at age
4 and 7 years. We highlight the diagnostic value of
urinary GC/MS in this condition, as neither CRD nor
ACRD can be diagnosed by conventional approaches
analysing standard plasma steroid hormones. Further-
more, an extended comparison of the urinary steroid
profiles of all available ACRD/CRD cases emphasises
the urinary biomarkers best able to differentiate these
genetic disorders when considering the differential
diagnosis of cases of premature adrenarche and
androgen excess disorders in childhood and
adolescence.
In these novel cases presenting with premature
adrenarche, more commonly diagnosed conditions
such as congenital adrenal hyperplasia (CAH) were
excluded. On this basis, 24-h urine collections were
used to assess the urinary steroid profile, upon which
the genetic testing was initiated. This led to the
identification of three novel mutations in the H6PD
gene. Case 1 was a compound heterozygote for a
previously described cytosine insertion into exon 2
causing a frameshift and nonsense codon severely
truncating the H6PDH protein, and a novel p.P146L
missense mutation, which we have shown through
in silico three-dimensional protein modelling to poten-
tially impact upon cofactor binding, thus rendering
NADPH production to be abolished. Case 2 was a
compound heterozygote for nonsense mutations
p.Q325X and p.Y446X, both of which severely truncate
the H6PDH protein ablating function. Together, these
three novel mutations bring the total described
mutations leading to loss of H6PDH function to eight.
We have previously described the adult presentation
of H6PDH deficiency in three females (4). In these
individuals, lifetime loss of 11b-HSD1-mediated clear-
ance of cortisol to cortisone and chronic HPA axis
activation has led to adrenal hyperplasia, exaggerated
adrenal androgen production and circulating hyper-
androgenemia resulting in a PCOS-like phenotype
(1, 2, 3). Adults presenting with ACRD may have had
a premature adrenarche in their childhood, which did
not come to clinical attention. We have also recently
identified two young males (age 8 and 11 years)
presenting with premature pubarche and adrenal
androgen excess due to dominant negative mutations
in the HSD11B1 gene, resulting in deficiency of
11b-HSD1 oxo-reductase activity (5). Given the mode
of inheritance in these two CRD cases, we have also
included the mothers, also carrying the HSD11B1
mutations, in the genetically defined CRD cohort.
We have now reported a total of ten cases in which
we can describe a continuum of clinical and bio-
chemical presentation, three adults and three children
with ACRD, and two adults and two children with CRD.Urinary steroid metabolite analysis is an important
tool for identifying steroid-related disorders and we have
extended this to now include the identification of
CRD/ACRD patients (10, 15, 16, 17). We show markers
that define not only the range in which ACRD and CRD
exists but also the difference between them. The
biomarker panel offers insight into the levels of a
range of urinary metabolites of steroid hormones that
are decreased (the cortisol derivatives, e.g. cortols) or
increased (the cortisone derivatives, e.g. cortolones, and
the urinary androgen metabolites An, Et and DHEA).
In addition, urinary steroid profiling offers a means to
assess HPA axis activity and adrenal output. The THF
C5a-THF/THE and cortols/cortolones ratios are useful
indicators of in vivo 11b-HSD1 activity highlighting
deficient 11b-HSD1 activity. The absolute values of
the cortisone metabolites THE and cortolones are robust
markers of the differences between ACRD and CRD
being elevated to a greater extent in ACRD compared
with CRD children with respect to the upper limits of
the age-matched reference ranges. In adults, the THE
and the cortolone values are markedly elevated in ACRD
compared with CRD cases, offering useful insight. The
THFC5a-THF/THE and cortol/cortolone ratios offer
the clearest distinction between ACRD and CRD, with
a value of !0.1 in the former ratio indicating ACRD.
We also observed that some ACRD cases have a low
value for the 5a-THF/THF ratio, indicating enhanced
5b-reductase activity, or concomitant deficiency
in 5a-reductase activity, though the basis for this
alteration in activity is unknown. Interestingly, the
opposite pattern, i.e. an increased 5a-THF/THF ratio,
with 5b-reductase deficiency is observed in patients
with apparent mineralocorticoid excess secondary
to mutations in 11b-HSD2 (18). It appears that
5a-reductase and 5b-reductase activities are intricately
linked to the cortisol–cortisone set point. On this
basis, we believe this relatively simple diagnostic tool
can define a case of CRD or ACRD offering a differential
diagnosis for premature adrenarche in children, or
PCOS in adult females. This could now be considered
as an additional resource when assessing patients with
unexplained hyperandrogenism.
Medical management of CRD and ACRD will vary.
Hydrocortisone treatment at an optimised dose regimen
may be sufficient to suppress HPA activity and reduce
adrenal androgen production in cases of CRD. However,
in cases of ACRD in which HPA axis activation is more
florid, increased activity of the 11b-HSD1 dehydro-
genase reaction, converting cortisol to cortisone, might
be expected to more rapidly inactivate hydrocortisone,
thereby reducing its potency. In these cases, it may
be more appropriate to administer a long-acting
synthetic glucocorticoid such as prednisolone or
dexamethasone, with the latter not being metabolised
by 11b-HSD1 at all. Where used in published cases of
ACRD, dexamethasone has effectively suppressed hyper-
androgenism and led to reversal of clinical phenotypeswww.eje-online.org
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congenital adrenal hyperplasia secondary to biosyn-
thetic defects, the risks of a negative impact on
metabolic parameters will need to be considered care-
fully taking into account sex and age of the individual
patient and the observed degree of HPA activation.
In the paediatric setting, this is especially important
when balancing the growth suppressive effects of
glucocorticoids over treatment against the potentially
detrimental consequences of ongoing hyperandrogenism.
In summary, urinary steroid profiling by GC/MS of
unresolved cases of adrenal hyperandrogenism in
patients with premature adrenarche, pubarche or
PCOS should form the ‘gold standard’ in the diagnosis
and differential diagnosis of ACRD/CRD and allow
further stratification to improve patient treatment and
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